Spruce Biosciences Announces Poster Presentations at the 2024 Annual Meeting of the Endocrine Society

Rhea-AI Summary

Spruce Biosciences (Nasdaq: SPRB) announced that three abstracts have been accepted for presentation at the 106th Annual Meeting of the Endocrine Society (ENDO 2024), taking place from June 1-4, 2024, in Boston.

The company will present final results from its Phase 2 POWER study of tildacerfont for the treatment of polycystic ovary syndrome (PCOS). Additionally, they will highlight comorbidities associated with congenital adrenal hyperplasia (CAH) and the importance of transitionary care between pediatric and adult endocrinology practices for CAH patients.

Positive

• Acceptance of three abstracts at ENDO 2024 indicates recognition of Spruce Biosciences' research.
• Presentation of final results from the Phase 2 POWER study on tildacerfont for PCOS could attract investor interest.
• Focus on comorbidities and transitionary care for CAH highlights the company's dedication to comprehensive healthcare solutions.

Negative

• No new financial data or revenue projections were provided in the PR.
• Potential risks if the Phase 2 POWER study results for tildacerfont are not favorable.
• No updates on pipeline progression beyond the mentioned studies, which could concern investors looking for broader development news.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that three submitted abstracts were accepted for the 106^th Annual Meeting of the Endocrine Society (ENDO 2024) taking place June 1-4, 2024, in Boston.

In a poster presentation, the company will present final results from its Phase 2 POWER study of tildacerfont for the treatment of polycystic ovary syndrome (PCOS). In two other poster presentations, the company will highlight the comorbidities associated with congenital adrenal hyperplasia (CAH) and standard of care treatment, as well as the need to formalize transitionary care between pediatric and adult endocrinology practices to improve biochemical outcomes that reduce the risk of morbidity and mortality in adults with CAH.

ENDO 2024 Poster Presentation Details

Title: A Randomized, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety and Efficacy of Tildacerfont in Adult Subjects with Polycystic Ovary Syndrome (PCOS) and Elevated Adrenal Androgens
Session Title: P058 – Reproductive Endocrinology: Polycystic Ovary Syndrome
Session Date & Time: 12:00 – 1:30 p.m. ET on June 2, 2024
Presenter: Ricardo Azziz, M.D., M.B.A., M.P.H., Professor, Obstetrics and Gynecology at University of Alabama at Birmingham School of Medicine
Authors: Yvette M. Poindexter, M.D., FACOG, M.B.A.; Maralisa Vanandel, BCPA, Daniel A. Dumesic, M.D.; Ricardo Azziz, M.D., M.B.A., M.P.H.; Richard Joseph Auchus, M.D., Ph.D.; Will Charlton, M.D.; Saba Sile, M.D.; Lubna Pal, MBBS, FRCOG

Title: Impact of Geography and Insurance on Healthcare Utilization Preferences of Individuals with Congenital Adrenal Hyperplasia
Session Title: P023 – Adrenal (Excluding Mineralocorticoids): Health Disparities in Adrenal
Session Date & Time: 12:15 – 1:45 p.m. ET on June 1, 2024
Presenter: Prasanth Surampudi, M.D., Associate Professor, Endocrinology, Diabetes, and Metabolism at U.C. Davis School of Medicine
Authors: Prasanth Surampudi, M.D.; Amir Hamrahian, M.D.; Will Charlton, M.D.; PJ Ramtin; Mitchell Geffner, M.D.

Title: The Treatment May Be Worse Than the Disease: The Real-World Clinical Burden of Disease and Treatment in Congenital Adrenal Hyperplasia
Session Title: P023 – Adrenal (Excluding Mineralocorticoids): Health Disparities in Adrenal
Session Date & Time: 12:15 – 1:45 p.m. ET on June 1, 2024
Presenter: Wenyu Huang, M.D., Ph.D., Associate Professor, Division of Endocrinology, Metabolism, and Molecular Medicine at Northwestern University Feinberg School of Medicine, and Amir Hamrahian, M.D., Associate Professor of Medicine, Division of Endocrinology, Diabetes and Metabolism at John Hopkins University
Authors: Wenyu Huang, M.D., Ph.D.; Will Charlton, M.D.; Saba Sile, M.D.; Christopher Dieyi, M.B.A., M.P.H.; Shayna Adams, M.P.H.; Jason Maynard, Ph.D.; Chris Barnes, Ph.D.; Amir Hamrahian, M.D.

The poster presentations will be available on the company’s website at the time of their respective poster sessions. Access more information about ENDO 2024 here.

About Spruce Biosciences

Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. Spruce is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy for patients suffering from classic congenital adrenal hyperplasia (CAH) and other endocrine disorders. To learn more, visit www.sprucebio.com and follow us on Twitter/X @Spruce_Bio, LinkedIn, Facebook and YouTube.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240522604348/en/

Media

Katie Beach Oltsik

Inizio Evoke Comms

(937) 232-4889

Katherine.Beach@inizioevoke.com

media@sprucebio.com

Investors

Samir Gharib

President and CFO

Spruce Biosciences, Inc.

investors@sprucebio.com

Source: Spruce Biosciences, Inc.

FAQ

What did Spruce Biosciences announce in their latest press release?

Spruce Biosciences announced that three abstracts have been accepted for presentation at the ENDO 2024 Annual Meeting.

When and where is the ENDO 2024 Annual Meeting?

The ENDO 2024 Annual Meeting will take place from June 1-4, 2024, in Boston.

What is Spruce Biosciences presenting at ENDO 2024?

Spruce Biosciences will present final results from its Phase 2 POWER study of tildacerfont for PCOS and highlight comorbidities in CAH and the importance of transitionary care.

What is the significance of the Phase 2 POWER study results for SPRB?

The final results of the Phase 2 POWER study for tildacerfont in treating PCOS can significantly impact Spruce Biosciences' stock performance and investor interest.

How does the acceptance of abstracts at ENDO 2024 affect SPRB?

The acceptance of three abstracts at ENDO 2024 suggests scientific recognition and may positively influence investor confidence in Spruce Biosciences.